# Immuneering Shares Hold Amid Survival Data

> Immuneering's pancreatic cancer drug shows 17.3-month survival but cash burn risks limit stock upside.
- Title: Immuneering Shares Hold Amid Survival Data · Seekingalpha
- Summary: Immuneering's pancreatic cancer drug shows 17.3-month survival but cash burn risks limit stock upside. Immuneering's pancreatic cancer treatment shows…
- Keywords: immuneering, pancreatic cancer, atebimetinib, cash burn, imrx, survival data, money, business, Shares, Hold, Survival, Data
- Source: Seekingalpha — https://seekingalpha.com/article/4955150-immuneering-stock-promising-survival-data-though-cash-discount-needs-scrutiny
- Author: Eric Cottrell
- Published: 2026-10-19T11:18:36+00:00
- Read time: 1 min
- Topics: immuneering, pancreatic cancer, atebimetinib, cash burn, imrx, survival data, money, business
## Early Clinical Data
Immuneering's pancreatic cancer drug shows 17.3-month median survival in early trials.
## Cash Burn Concerns
Company has $182.7M liquidity with annual cash outflows near $70M.
## Investment Rating
Analyst maintains 'Hold' rating due to valuation risks and cash buffer concerns.
## Key takeaway

Immuneering's pancreatic cancer treatment shows 17.3-month survival in early trials but significant cash burn could prevent stock buy rating.